Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that must flexibly handle outsourced production, which can come suddenly and often must quickly be ramped up. For example, to meet the urgent need for COVID-19 related therapies and vaccines early in the pandemic, Thermo Fisher Scientific, a world leader in serving science with annual revenue of approximately $35 billion, had to expand its manufacturing capacity quickly and dramatically at its Greenville, North Carolina plant to meet urgent demand. Thermo Fisher offers a comprehensive range of industry-leading services for small and
The post Distributed Control System Facilitates Expansion for New Drugs Produced by Contract Manufacturing Organization appeared first on Pharma Mirror Magazine.
